SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
3.860
-0.090 (-2.28%)
At close: Oct 29, 2026, 4:00 PM EDT
3.760
-0.100 (-2.59%)
After-hours: Oct 29, 2026, 7:30 PM EDT
SCYNEXIS Employees
SCYNEXIS had 18 employees as of December 31, 2025. The number of employees decreased by 10 or 35.71% compared to the previous year. That makes SCYNEXIS the 38,711th largest employer in the world and 5,608th in the United States.
Employees
18
Change (1Y)
-10
Growth (1Y)
-35.71%
Revenue / Employee
$1,067,556
Profits / Employee
-$568,611
Market Cap
38.41M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 18 | -10 | -35.71% |
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2023 | 29 | -7 | -19.44% |
| Dec 31, 2022 | 36 | -20 | -35.71% |
| Dec 31, 2021 | 56 | 18 | 47.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| InterCure | 285 |
| Zhengye Biotechnology Holding | 269 |
| China Pharma Holdings | 215 |
| Rockwell Medical | 157 |
| Cumberland Pharmaceuticals | 88 |
| Aytu BioPharma | 76 |
| Incannex Healthcare | 12 |
| Talphera | 12 |
SCYX News
- 18 hours ago - SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 7 days ago - Scynexis announces topline results from SCY-247 trial - TheFly
- 7 days ago - SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases - GlobeNewsWire
- 8 days ago - SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek - GlobeNewsWire
- 8 days ago - SCYNEXIS Slides: Corporate presentation - Filings
- 23 days ago - Scynexis completes study of SCY-770 - TheFly
- 23 days ago - SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - GlobeNewsWire
- 4 weeks ago - Brookline says BARDA contract a major positive for Scynexis’ SCY-247 program - TheFly